Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.

doi:10.1021/jm3017706

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.

Journal of medicinal chemistry - 11 Jul 2013

Wang Yuanxiang, Kaiser Christine E, Frett Brendan, Li Hong-Yu

Abstract excerpt

The RAS proteins play a role in cell differentiation, proliferation, and survival. Aberrant RAS signaling has been found to play a role in 30% of all cancers. KRAS, a key member of the RAS protein family, is an attractive cancer target, as frequent point mutations in the KRAS gene render the protein constitutively active. A number of attempts have been made to target aberrant KRAS signaling by identifying small...

Topics

Cell Cycle Proteins
Humans
Models, Biological
Molecular Structure
Molecular Targeted Therapy
Mutation
Protein Serine-Threonine Kinases
Proto-Oncogene Proteins
Signal Transduction
Small Molecule Libraries
ras Proteins
Polo-Like Kinase 1

Source

Open in PubMed Open full text

Identifiers

PMID: 23566315
DOI: 10.1021/jm3017706
PMCID: PMC4666308

Genes

KRAS
PLK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics